2-(4-formylbenzylidene)-1-(6-methyl-2H-[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazine | 1392812-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(4-formylbenzylidene)-1-(6-methyl-2H-[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazine
• 英文别名: 4-[[(6-methyl-[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazinylidene]methyl]benzaldehyde
• CAS: 1392812-76-8
• 化学式: C₁₉H₁₅N₃O₃
• 分子量: 333.346
• InChiKey: ZJXRTWQJAHXWPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.53
• 重原子数：
  25.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  72.81
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  甲醇 、 2-(4-formylbenzylidene)-1-(6-methyl-2H-[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazine 在 tetrafluoroboric acid 作用下， 反应 0.03h， 以95%的产率得到2-(4-(dimethoxymethyl)benzylidene)-1-(6-methyl[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazine
  参考文献：
  名称：

  Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors

  摘要：

  Metallo-beta-lactamases (MBLs) represent one of the most important and widespread mechanisms of resistance to beta-lactam antibiotics (including the life-saving carbapenems), against which no clinically useful inhibitors are currently available. We report herein a structure-based high-throughput docking (HTD) campaign on three clinically-relevant acquired MBLs (IMP-1, NDM-1 and VIM-2). The initial hit NF1810 (1) was optimized providing the broad-spectrum inhibitor 3i, which is able to potentiate the in vitro activity of cefoxitin on a VIM-2-producing E. coli strain.

  DOI：

  10.3109/14756366.2016.1172575
• 作为产物：
  描述：

  2-(4-(diethoxymethyl)benzylidene)-1-(6-methyl-2H-[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazine 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 反应 14.0h， 以88%的产率得到2-(4-formylbenzylidene)-1-(6-methyl-2H-[1,3]dioxolo[4,5-g]quinolin-8-yl)hydrazine
  参考文献：
  名称：

  Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1

  摘要：

  Plasmodium falciparum subtilisin-like protease 1 (PfSUB1) is a serine protease that plays key roles in the egress of the parasite from red blood cells and in preparing the released merozoites for the subsequent invasion of new erythrocytes. The development of potent and selective PfSUB1 inhibitors could pave the way to the discovery of potential antimalarial drugs endowed with an innovative mode of action and consequently able to overcome the current problems of resistance to established chemotherapies. Through the screening of a proprietary library of compounds against PfSUB1, we identified hydrazone 2 as a hit compound. Here we report a preliminary investigation of the structure-activity relationships for a class of PfSUB1 inhibitors related to our identified hit. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.023